Nur Adriana Athirah Muhammad Rhadi1*, Wan Ahmad Syazani Mohamed2, Nur Syahzanani Aqilah Jami’an3
1. Faculty of Applied Sciences, Universiti Teknologi MARA, 40450, Shah Alam, Selangor, Darul Ehsan, Malaysia
2. Nutrition, Metabolic and Cardiovascular Research Centre (NMCRC), Institute for Medical Research, National Institutes of Health (NIH), Block C, No.1, Jalan Setia Murni U13/52, Seksyen U13 Setia Alam, 40170 Shah Alam, Selangor, Malaysia
3. Faculty of Applied Sciences, Universiti Teknologi MARA, Cawangan Perlis, Kampus Arau, 02600, Arau, Perlis
*Corresponding author: Wan Ahmad Syazani Bin Mohamed.
ABSTRACT
INTRODUCTION: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder that is closely related to insulin resistance and progressive beta-cell dysfunction due to factors like hyperglycaemia. Sodium glucose co-transporter-2 inhibitors (SGLT-2i), which was originally used to treat hyperglycaemia, have shown promising metabolic benefits through its impact on insulin sensitivity and glycaemic control. While SGLT-2i has been linked with metabolic benefits in T2DM patients, its direct impact on insulin resistance and beta-cell function remains insufficiently studied, especially in T2DM patients within the Malaysian population.
OBJECTIVE(S): This study aims to investigate the effects of SGLT-2i on insulin-related metabolic parameters among Malaysian T2DM patients.
MATERIALS & METHODS: A cross-sectional study was conducted involving 280 adults with T2DM, divided into two groups: 137 patients treated with SGLT-2i for 6 months (receiving either dapagliflozin at 10 mg/day or empagliflozin at 10–25 mg/day) and 143 patients not receiving SGLT-2i (administered other oral antidiabetic drugs (OADs)). Demographic data and insulin-related metabolic parameters were recorded. Comparison between groups for fasting blood glucose (FBG), fasting insulin, homeostatic model assessment of insulin resistance (HOMA-IR) and homeostatic model assessment of beta-cell function (HOMA-BCF) were analysed using Wilcoxon rank sum test.
RESULTS: FBG, fasting insulin and HOMA-IR were lower in the SGLT-2i group compared to the non-SGLT-2i group, with FBG 6.7 (3.1) nmol/L vs. 6.8 (3.4) nmol/L (p = 0.599), fasting insulin: 10.6 (11.3) μIU/mL vs. 11.3 (14.2) μIU/mL (p = 0.567), and HOMA-IR: 3.4 (3.9) vs. 3.5 (5.4) (p = 0.518), suggesting better glycaemic control and insulin sensitivity in those patients who received SGLT-2i. HOMA-BCF was higher in the SGLT-2i group (32.9 [41.4]%) compared to the non-SGLT-2i group (31.8 [40.0]%) (p = 0.68), indicating better beta-cell function, reflecting improved pancreatic insulin secretory capacity in those administered SGLT-2i.
CONCLUSION: The SGLT-2i treatment has shown to effectively enhance insulin sensitivity and beta-cell function in T2DM. Thus, highlighting its potential as an impactful antidiabetic drug capable of improving key markers of insulin resistance and pancreatic beta-cell performance, especially among Malaysian T2DM patients.
KEYWORDS: Type 2 Diabetes Mellitus, Sodium Glucose Co-transporter-2 Inhibitor, Insulin Resistance, Beta-cell Function, Fasting Insulin


